INNIO N.V. Ordinary Shares vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? INNIO N.V. Ordinary Shares trades at $16 (market cap $13.73B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B). The key difference: INNIO N.V. Ordinary Shares is far larger — about 2.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 1 Days on average.
| INIO | IOVA | |
|---|---|---|
Market Cap | $13.73B | $6.57B |
Volume | 5,012,195 | 11,838,721 |
Sector | Industrials | Health |
52-Week High | $41.13 | $14.82 |
52-Week Low | $16.50 | $1.81 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $15.39B | $6.50B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.
Read more on INIO →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →